Tying U.S. drug prices to an international reference price would have lowered 2020 US spending on selected prescription drugs by 52.3% or $83.5 billion, from $159.9 billion at US net prices to $76.3 billion.
This report is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.